Hansa Pink Sheet Buy Hold or Sell Recommendation

HNSBF Stock  USD 5.20  0.72  12.16%   
Assuming the 90 days horizon and your bold attitude towards risk, our recommendation regarding Hansa Biopharma AB is 'Strong Hold'. Macroaxis provides Hansa Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding HNSBF positions. The advice algorithm takes into account all of Hansa Biopharma's available fundamental, technical, and predictive indicators you will find on this site.
  
The advice is provided from Hansa Biopharma's buy-and-hold perspective. Please check Hansa Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Hansa and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Hansa Biopharma AB.

Execute Hansa Biopharma Buy or Sell Advice

The Hansa recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Hansa Biopharma AB. Macroaxis does not own or have any residual interests in Hansa Biopharma AB or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Hansa Biopharma's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Hansa BiopharmaBuy Hansa Biopharma
Strong Hold

Volatility

Details

Hype Condition

Details

Current Valuation

Details

Odds of Distress

Details

Economic Sensitivity

Details

Analyst Consensus

Not Available
Details

Reporting Quality (M-Score)

Details
For the selected time horizon Hansa Biopharma AB has a Risk Adjusted Performance of 0.0016, Jensen Alpha of (0.17), Total Risk Alpha of (0.61) and Treynor Ratio of (0.03582)
We provide advice to complement the regular expert consensus on Hansa Biopharma. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Hansa Biopharma AB is not overpriced, please check out all Hansa Biopharma fundamentals, including its price to sales, cash per share, number of employees, as well as the relationship between the ebitda and book value per share . Given that Hansa Biopharma AB has a price to book of 6.59 X, we strongly advise you to confirm Hansa Biopharma AB market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Hansa Biopharma Returns Distribution Density

The distribution of Hansa Biopharma's historical returns is an attempt to chart the uncertainty of Hansa Biopharma's future price movements. The chart of the probability distribution of Hansa Biopharma stock daily returns describes the distribution of returns around its average expected value. We use Hansa Biopharma AB price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Hansa Biopharma returns is essential to provide solid investment advice for Hansa Biopharma.
Mean Return-0.03Value At Risk-2.22
Potential Upside0.00Standard Deviation5.27
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Hansa Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Hansa Biopharma Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Hansa Biopharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Hansa Biopharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Hansa pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over NYSE Composite
-0.17
β
Beta against NYSE Composite1.11
σ
Overall volatility
5.07
Ir
Information ratio -0.03

Hansa Biopharma Volatility Alert

Hansa Biopharma AB exhibits very low volatility with skewness of 4.19 and kurtosis of 34.82. However, we advise investors to further study Hansa Biopharma AB technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Hansa Biopharma's pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Hansa Biopharma's pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Hansa Biopharma Fundamentals Vs Peers

Comparing Hansa Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Hansa Biopharma's direct or indirect competition across all of the common fundamentals between Hansa Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Hansa Biopharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Hansa Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Hansa Biopharma to competition
FundamentalsHansa BiopharmaPeer Average
Return On Equity(1.01) %(0.31) %
Return On Asset(0.30) %(0.14) %
Current Valuation189.89 M16.62 B
Shares Outstanding52.44 M571.82 M
Shares Owned by Insiders7.37 %10.09 %
Shares Owned by Institutions42.38 %39.21 %
Price to Earning(46.57) X28.72 X
Price to Book6.59 X9.51 X
Price to Sales16.29 X11.42 X
Revenue33.88 M9.43 B
Gross Profit18.45 M27.38 B
EBITDA(538.83 M)3.9 B
Net Income(548.28 M)570.98 M
Cash and Equivalents60.15 M2.7 B
Cash per Share1.58 X5.01 X
Debt to Equity2.29 %48.70 %
Current Ratio6.42 X2.16 X
Book Value Per Share1.50 X1.93 K
Cash Flow from Operations(481.17 M)971.22 M
Earnings Per Share(0.65) X3.12 X
Number of Employees14518.84 K
Beta0.88-0.15
Market Capitalization277.47 M19.03 B
Total Asset1.01 B29.47 B
Working Capital86 M1.48 B
Current Asset105 M9.34 B
Current Liabilities19 M7.9 B
Net Asset1.01 B

About Hansa Biopharma Buy or Sell Advice

When is the right time to buy or sell Hansa Biopharma AB? Buying financial instruments such as Hansa Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Hansa Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Services Thematic Idea Now

Services
Services Theme
Companies involved in delivering services to business or consumers across different industries and sectors. The Services theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Services Theme or any other thematic opportunities.
View All  Next Launch
Please check Hansa Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Hansa Pink Sheet analysis

When running Hansa Biopharma AB price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Please note, there is a significant difference between Hansa Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Hansa Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hansa Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.